These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9060963)

  • 1. Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA
    J Natl Cancer Inst; 1997 Mar; 89(5):395-6. PubMed ID: 9060963
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R; Verweij J; Bontenbal M; Kruit WH; Seynaeve C; Schmitz PI; Stoter G
    J Natl Cancer Inst; 1996 Oct; 88(19):1393-8. PubMed ID: 8827017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Paradoxical myelosuppression with granulocyte-stimulating factor (G-CSF) and simultaneous administration chemotherapy].
    Sanz Ortiz J; Llamazares A; López-Vega JM
    Med Clin (Barc); 1993 Sep; 101(7):276. PubMed ID: 7538188
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of G-CSF for breast cancer chemotherapy].
    Suzuki Y; Saito Y; Tokuda Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():572-4. PubMed ID: 17679213
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it.
    Hassan HT; Zander AR
    J Hematother; 1996 Aug; 5(4):407-14. PubMed ID: 8877716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy.
    Meropol NJ; Miller LL; Korn EL; Braitman LE; MacDermott ML; Schuchter LM
    J Natl Cancer Inst; 1992 Aug; 84(15):1201-3. PubMed ID: 1378905
    [No Abstract]   [Full Text] [Related]  

  • 9. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
    Demirer T; Rowley S; Buckner CD; Appelbaum FR; Lilleby K; Storb R; Schiffman K; Bensinger WI
    J Clin Oncol; 1995 Jul; 13(7):1714-9. PubMed ID: 7541450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells.
    Winter JN; Lazarus HM; Rademaker A; Villa M; Mangan C; Tallman M; Jahnke L; Gordon L; Newman S; Byrd K; Cooper BW; Horvath N; Crum E; Stadtmauer EA; Conklin E; Bauman A; Martin J; Goolsby C; Gerson SL; Bender J; O'Gorman M
    J Clin Oncol; 1996 Jan; 14(1):277-86. PubMed ID: 8558209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical efficacy of rhIL-11.
    Reynolds CH
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):32-40. PubMed ID: 11033836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of granulocyte colony-stimulating factor on peripheral white blood cell and platelet counts in mice pretreated with anticancer drugs].
    Mizushima Y; Morikage T; Konishi K; Yano S
    Hokkaido Igaku Zasshi; 1990 Nov; 65(6):628-31. PubMed ID: 1702402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necrosis of uninvolved bone marrow following filgrastim administration in a patient with Burkitt lymphoma undergoing chemotherapy.
    Ding L; Rawal A; Luikart S; Wadhwa P
    Br J Haematol; 2012 Oct; 159(1):2. PubMed ID: 22881409
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
    Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
    J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin.
    Ballestrero A; Ferrando F; Garuti A; Gonella R; Stura P; Sessarego M; Amoroso D; Boccardo F; Patrone F
    Oncology; 2000 Jun; 59(1):7-13. PubMed ID: 10895059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
    Ishiguro H; Kitano T; Yoshibayashi H; Toi M; Ueno T; Yasuda H; Yanagihara K; Garbo CL; Fukushima M
    Ann Oncol; 2008 May; 19(5):1019; author reply 1019-20. PubMed ID: 18325914
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.